logo

IPO

Share

petco jan14 Pet care retailer Petco Health and Wellness Company Inc.'s shares surged around 63% in the first day trading on Thursday after the Initial Public Offering, reflecting strong demand for pets as majority of people are confined to their homes during the Covid-19 pandemic crisis. On the Nasdaq, the shares, which are trading under the ticker symbol WOOF, opened at $26, reflecting 44% above its IPO pric

AUTO1 Group SE, Europe's leading digital automotive platform, announced intention to list shares on the regulated market (Prime Standard) of the Frankfurt Stock Exchange. The planned offering is expected to comprise newly issued shares from a capital increase and existing shares as well as shares in...

Affirm priced its initial public offering of class A common stock at $49.00 per share. The company is offering 24.6 million shares of its class A common stock. The shares are expected to begin trading on the Nasdaq Global Select Market on January 13, 2021 under the symbol, AFRM. The offering is anticipated...

berkeleylights jan13 The lockup period of Berkeley Lights (BLI) ends on January 13. The Emeryville, California-based Berkeley Lights Inc. is a commercial-stage digital cell biology company developing biotherapeutics and other cell-based products.

pandiontherapeutics jan13 The lockup period of Watertown, Massachusetts-based Pandion Therapeutics (PAND) expires tomorrow (January 13, 2021). Pandion Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for patients suffering from autoimmune diseases.

alxoncology jan13 The lockup period of Burlingame, California-based ALX Oncology Holdings Inc. (ALXO) ends on January 13. ALX Oncology Holdings is a clinical-stage immuno-oncology company developing therapies targeting CD47 checkpoint pathway for blood and solid tumor cancers.

relay jan11 The lockup period of Relay Therapeutics (RLAY) expires today, i.e., January 12. Cambridge, Massachusetts-based Relay Therapeutics is a clinical-stage precision medicines company, with an initial focus in oncology.

ipolockupexpirationalert jan11 The lockup period of GoHealth Inc.(GOCO) ends on January 11. GoHealth is a Chicago, Illinois-based company with a mission to improve access to medicare and health insurance plans for consumers.

gracellbiotechnologies jan09 Gracell Biotechnologies is scheduled to make its debut on the Nasdaq Global Select Market today (January 8), under the ticker symbol "GRCL." The Suzhou, China-based Gracell Biotechnologies is a global clinical-stage biopharmaceutical company developing CAR-T cell therapies for cancer through its proprietary technology platforms—FasTCAR and TruUCAR.

cullinanmanagement jan09 Cullinan Management is scheduled to make its debut on the Nasdaq Global Select Market today (January 8), under the ticker symbol "CGEM." Cambridge, Massachusetts-based Cullinan Management, Inc., which was founded in 2016, is a biopharmaceutical company developing oncology and immuno-oncology therapies with transformative potential for cancer patients.

Playtika Holding Corp. announced the launch of its initial public offering of 69.5 million shares of its common stock. The IPO price is currently expected to be between $22.00 and $24.00 per share. The offering consists of 21.7 million shares of common stock offered by Playtika and 47.8 million shares...

inventiva jan05 The lockup period of Inventiva SA (IVA) ends on January 6. Daix, France-based Inventiva is a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, mucopolysaccharidoses, or MPS, and other diseases.

poseidatherapeutics jan05 The lockup period of Poseida Therapeutics (PSTX) ends tomorrow, i.e., January 6. San Diego, California-based Poseida Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies to treat a range of cancers.

nkarta jan05 The lockup period of Nkarta Inc. (NKTX) expires tomorrow, i.e. on Jan 6. South San Francisco, California-based Nkarta Inc. is a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer.

MEDIROM Healthcare Technologies Inc. (MRM) said that it has priced its initial public offering of 800,000 American Depositary Shares at a price of US$15.00 per ADS. Each ADS represents one common share of MEDIROM. The ADSs are expected to begin trading on the Nasdaq Capital Market on December 29,...

Follow RTT